SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC armsAll patients remaining in the 30 mg onvansertib + FOLFIRI/bev arm have now exceeded 21 months on treatmentCompany preparing for…

CRDF

Related stories